Close Menu

NEW YORK – Daiichi Sankyo on Thursday announced it had entered into a collaboration with AstraZeneca to evaluate the combination of its experimental HER3-directed DXd antibody drug conjugate, patritumab deruxtecan (U3-1402) in combination with AstraZeneca's TKI osimertinib (Tagrisso) in a two-part Phase I clinical trial for the treatment of patients with advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.